Contrast

Contact

Share

Donate

MyChart

Help

Michael D. Holmes named Yale New Haven Hospital chief operating officer

Thursday, January 28, 2021

New Haven, CT (Jan. 28, 2021) – Yale New Haven Hospital (YNHH) recently named Michael D. Holmes to the position of chief operating officer (COO). Holmes has more than 32 years of senior executive experience in the healthcare industry.

In this role, he will be responsible for overseeing all YNHH budget mitigation activities including the financial relationship with Yale School of Medicine. Holmes will retain his existing responsibilities as the hospital incident commander, responsible for hospital response during a crisis, such as COVID-19. He will also oversee clinical services for Behavioral Health, Emergency Medicine, Laboratory Services, Pathology, Respiratory Care and all key support services.

Holmes started at YNHH as the senior vice president of Operations in 2013. He led the hospital team in the extremely successful integration of Saint Raphael’s Hospital into YNHH. The resulting 1541 bed hospital across two campuses saved over $600 million in economy of scale savings and the investment of more than $250 million in capital, made Yale New Haven Hospital one of the top 10 largest hospitals in the country.

Most recently, Holmes, as the Incident Command Officer, lead Yale New Haven Hospital in its exemplary COVID-19 preparations and response. He led a team that converted 200 hospital beds and 28 patient care units for a COVID-19 positive inpatient population that has treated over 4,500 patients and peaked at a one day COVID-19 census of 450 patients in April 2020. Of the 450, 120 patients were in the ICU and 90 were on mechanical ventilators.

Prior to joining YNHH, Holmes was the executive vice president and COO at Franciscan St. James Health in Chicago. Prior leadership appointments include COO and VP positions with Ascension Health, St. Luke’s South in Jacksonville, FL and Trinity Health, Mount Carmel Health System in Columbus, OH.

Michael holds a Bachelor of Science in Public Health Administration from Indiana University and a Master of Science in Administration from the University of Notre Dame.

Michael has vast experience with community boards, some of which include Presence Health, United Way of Greater New Haven, New Haven Habitat for Humanity and Silver Hill Hospital in New Caanan, CT. Michael and his wife Renee have two children, Justin and Nicole.

Yale New Haven Hospital (YNHH), part of Yale New Haven Health, is a nationally recognized, 1,541-bed, not-for-profit hospital serving as the primary teaching hospital for the Yale School of Medicine (YSM). Founded as the fourth voluntary hospital in the U.S. in 1826, today, YNHH has two New Haven-based campuses, and also includes Yale New Haven Children's Hospital, Yale New Haven Psychiatric Hospital and Smilow Cancer Hospital. YNHH has received Magnet designation from the American Nurses Credentialing Center, the nation’s highest honor of nursing excellence. YNHH has a combined medical staff of about 4,500 university and community physicians practicing in more than 100 specialties. www.ynhh.org

Similar Articles

9/15/2021

Marna Borgstrom to retire in 2022 as CEO of Yale New Haven Health

New Haven, CT (Sept. 15, 2021) – After more than 43 years of exceptional service, Marna P. Borgstom has announced her intent to retire as chief executive officer of Yale New Haven Health. Her retirement is effective on March 25 2022.

9/15/2021

Christopher O’Connor to become CEO of Yale New Haven Health

New Haven, CT (Sept. 15, 2021) – Christopher O’Connor has been named the CEO of Yale New Haven Health (YNHHS), effective March 25, 2022 when current CEO Marna P. Borgstrom retires, announced Vince Calarco, Chair of the YNHHS Board of Trustees. O’Connor currently serves as president of the Health System having been named to that position in August of 2020.

9/1/2021

Outpatient Monoclonal Antibody Treatment decreases hospitalization risk in COVID-19 patients

New Haven, CT (September 1, 2021) – While not a new treatment, monoclonal antibody therapy is being administered more regularly and effectively to patients with mild to moderate COVID-19 with excellent results.